Researchers have identified new roles for a protein long known to protect against severe flu infection -- among them, raising the minimum number of viral particles needed to cause sickness.

People living with HIV may also have to manage other health conditions like cardiovascular disease, type 2 diabetes, ...

The COVID-19 pandemic has taught us all the importance of educating the public about viral infections. Besides educating the general public, we need to equip the next generation of scientists by ...

(Howard Dean, 11/13) Miami Herald: CDC Numbers Offer Good News On HIV Infections Overall But Reveal A Crisis For Latinos When the Centers for Disease Control and Prevention published data in May of ...

From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...

have expressed concerns over the high rates of stigmatization against women and children living with the Human Immunodeficiency Virus (HIV). The local and international organizations also ...

Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of genetics and unique immune responses, according to a study of such ...

Rwanda is facing its first ever Marburg virus outbreak. Beginning in late September, 62 cases and 15 deaths had been reported by 17 October, mostly among healthcare workers in Kigali, the capital ...

A new, more infectious strain of the potentially deadly mpox virus has been found in Germany for the first time, health chiefs in the country have said. The Robert Koch Institute (RKI), Germany's ...

Doctors and front-line workers are watching closely as HIV rates increase significantly in Alberta. An annual Alberta Health report reveals the number of new HIV cases jumped by 73 per cent last ...

Credit: Ground Picture via Shutterstock. Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase II trials, following promising results from a 48-week study. The ...

The data was presented at the ID Week 2024. At 48 weeks, the investigational combination maintained a high rate (n=49; 94.2%) of viral suppression (HIV-1 RNA <50 copies/mL) in virologically ...